{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 45,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a 'plus' sign to visually bridge existing products with late-stage pipeline assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/22",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.15,
        "y": 0.33
      },
      "kind": "image",
      "text": "Existing CVRM products: Farxiga, Andexxa, Lokelma, Seloken XL, Roxadustat, Brilinta, Crestor",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cd91891-4b3a-4270-9ce7-84d48f7056b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.15,
        "y": 0.78
      },
      "kind": "list",
      "text": "Early-stage pipeline: mitiperstat, AZD3427, AZD0780, AZD5004, AZD5462, AZD6234, AZD9550",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f518888-d8bd-4eed-a779-102a53351eea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Opportunity to enhance existing CVRM portfolio with ongoing late-stage trials",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "838a903a-4375-428d-a404-84b296c5241b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.15,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Advancing early-stage pipeline",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f9d8406-3b7c-420a-acc3-7ec1ade754a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.53,
        "y": 0.33
      },
      "kind": "table",
      "text": "Late-stage trials: baxdrostat (u/r HTN), zibotentan/dapagliflozin (CKD w/ high proteinuria), balcinerone/dapagliflozin (CKD w/ HF), baxdrostat/dapagliflozin (CKD w/ uHTN), Wainua (ATTR-CM)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "812b48c4-c3f8-4cfd-aec8-50321cbad4dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.95,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Future expansion of CVRM portfolio with numerous ongoing late-stage, early-stage trials",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef4f56e5-1cb3-4e2a-9a80-8ac2b9a0b32b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "BioPharmaceuticals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "251c8fb2-d340-488d-bffe-350ea926fe88",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2befda1f-982f-4227-b4cc-56b5c24811dc",
      "evidence": "table/data: Late-stage trials: baxdrostat (u/r HTN), zibotentan/dapagliflozin (CKD w/ high proteinuria), balcinerone/dapagliflozin (CKD w/ HF), baxdrostat/dapagliflozin (CKD w/ uHTN), Wainua (ATTR-CM)",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "pipeline-overview",
      "slug": null,
      "matchId": "6b9a9674-527d-4e8e-bd99-217899b3a9e0",
      "evidence": "Categorization of assets into existing, late-stage, and early-stage",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}